Alkem Laboratories Limited (NSE:ALKEM) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Shareholders might have noticed that Alkem Laboratories Limited (NSE:ALKEM) filed its quarterly result this time last week. The early response was not positive, with shares down 4.1% to ₹5,368 in the past week. Alkem Laboratories reported in line with analyst predictions, delivering revenues of ₹37b and statutory earnings per share of ₹193, suggesting the business is executing well and in line with its plan. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
Following the latest results, Alkem Laboratories' 21 analysts are now forecasting revenues of ₹166.8b in 2027. This would be a notable 11% improvement in revenue compared to the last 12 months. Per-share earnings are expected to increase 7.3% to ₹194. Before this earnings report, the analysts had been forecasting revenues of ₹165.4b and earnings per share (EPS) of ₹195 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
View our latest analysis for Alkem Laboratories
There were no changes to revenue or earnings estimates or the price target of ₹5,941, suggesting that the company has met expectations in its recent result. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Alkem Laboratories, with the most bullish analyst valuing it at ₹6,850 and the most bearish at ₹4,590 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Alkem Laboratories' growth to accelerate, with the forecast 14% annualised growth to the end of 2027 ranking favourably alongside historical growth of 8.1% per annum over the past five years. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 12% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Alkem Laboratories is expected to grow at about the same rate as the wider industry.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. The consensus price target held steady at ₹5,941, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Alkem Laboratories going out to 2029, and you can see them free on our platform here..
However, before you get too enthused, we've discovered 1 warning sign for Alkem Laboratories that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.